Is Becton Dickinson (BDX) overvalued or fairly valued?

MarketChacha shows Becton Dickinson's valuation in context — a forward P/E of about 11.4, a price-to-book of about 1.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Becton Dickinson (BDX)?

Becton Dickinson last traded at $152.76 (-0.7% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Becton Dickinson

BDX · NYSE · Healthcare · United States

$152.76-0.7%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:36 PM

Snapshot

TickerBDX

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees60,000

HeadquartersFranklin Lakes, United States

Market cap$42.1B

P/B1.7

Volume420.46K

Websitewww.bd.com

Filings tracked0

About Becton Dickinson

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.4%
Institutions99.1%
Public & other0.5%

1,914 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.9.49%
Vanguard Capital Management LLC6.71%
Vanguard Portfolio Management LLC5.56%
State Street Corporation5.02%
First Eagle Investment Management, LLC4.33%
Invesco Ltd.3.69%
T. Rowe Price Investment Management, Inc.3.52%
Massachusetts Financial Services Co.3.30%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $5.1B · EPS 4.09

Est. earnings growth +3.4%

Next fiscal year

Rev $19.7B · EPS 13.42

Est. earnings growth +6.8%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$127.5952-wk range$187.35

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about BDX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.